Osimertinib is marketed under different names depending on the country. The following table focuses on brands for which current source documentation was located.
| Brand | Active ingredient | Strength identified | Company / manufacturer evidence |
|---|---|---|---|
| Tagrisso | Osimertinib | 80 mg | AstraZeneca |
| Tagrix | Osimertinib | 80 mg | Beacon Pharmaceuticals |
| Osicent | Osimertinib | 80 mg | Incepta Pharmaceuticals |
| Osimert | Osimertinib | 80 mg | Everest Pharmaceuticals |
Tagrisso is the reference product. DailyMed identifies AstraZeneca Pharmaceuticals LP as its U.S. packager, while EMA identifies Tagrisso as an authorised osimertinib medicine.
Beacon’s official product page identifies Tagrix as osimertinib 80 mg and lists tablet formulation and 80 mg strength.
Incepta’s official product page identifies Osicent 80 as containing osimertinib mesylate equivalent to 80 mg of osimertinib.
Everest’s official product catalogue identifies Osimert as osimertinib 80 mg, and Everest’s newsroom states that Osimert 80 mg was launched for export in 2018.
Important distinction
These brands should not be treated as interchangeable commercial products. They may contain the same active ingredient but can have different manufacturers, packaging, regulatory approvals and supply channels.
Other brands
Other osimertinib brands exist in different markets. A brand list should therefore be treated as market-specific rather than universal.